Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy

Enzyme replacement therapy (ERT) for Fabry disease (deficiency of α-galactosidase A, α-Gal) with recombinant α-Gals (agalsidase alfa and agalsidase beta) is widely available and improves some of the clinical manifestations and biochemical findings. However, recent reports suggest that recurrent admi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsukimura, Takahiro, Tayama, Yuya, Shiga, Tomoko, Hirai, Kanako, Togawa, Tadayasu, Sakuraba, Hitoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548986/
https://www.ncbi.nlm.nih.gov/pubmed/33072516
http://dx.doi.org/10.1016/j.ymgmr.2020.100650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548986/
https://www.ncbi.nlm.nih.gov/pubmed/33072516
http://dx.doi.org/10.1016/j.ymgmr.2020.100650

Ejemplares similares